Revvity, Inc. (RVTY) Stock Analysis

Company Overview

Revvity, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing health sciences solutions, technologies, and services that include instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training, and various software products. The company's operations are anchored by a substantial workforce of 11,000 employees, reflecting a significant physical and operational footprint within the specialized life sciences supply chain. As of the latest reported data, Revvity, Inc. holds a market capitalization of $9.38B, which positions it as a large-cap entity capable of influencing market dynamics within its niche. The annual revenue generated over the trailing twelve months is $2.86B, a figure that, when combined with its market cap, indicates a valuation premium relative to its current earnings power and suggests the market places high value on its future growth prospects or proprietary technology assets.

Financial Health

The company reported a trailing twelve-month revenue of $2.86B and generated net income of $239.88M, while its EBITDA stood at $840.93M, revealing a cost structure where operating expenses and taxes consume a significant portion of gross revenue before reaching the bottom line. This gap between revenue and net income highlights the substantial fixed costs inherent in manufacturing instruments and developing assay platforms, which must be covered to achieve profitability. The business produced free cash flow of $523.28M, a metric that demonstrates strong operational liquidity and the capacity to fund capital expenditures, research and development, or debt reduction without external financing. Profitability is characterized by a gross margin of 54.8%, indicating efficient production and pricing power; an operating margin of 20.1%, showing effective control over operational overhead; and a profit margin of 8.4%, which reflects the final return on sales after all expenses. Liquidity management is assessed by comparing total cash of $919.86M against total debt of $3.40B, resulting in a debt-to-equity ratio of 46.87, which suggests a leveraged balance sheet where debt obligations are substantial relative to equity. Despite the leverage, the current ratio of 1.68 indicates a healthy short-term liquidity position, as current assets are significantly higher than current liabilities. Return metrics further illustrate capital efficiency, with a return on equity of 3.2% and a return on assets of 2.2%, figures that suggest management effectiveness in generating returns is currently modest relative to the level of capital deployed.

Valuation Assessment

Valuation multiples show a trailing P/E ratio of 40.73 and a forward P/E of 13.98, implying that the market currently prices in significant earnings growth as the forward multiple is markedly lower than the trailing multiple. The price-to-book ratio is 1.30, indicating that the stock trades at a modest premium over its book value, which is typical for capital-intensive or technology-driven firms where intangible assets and future earnings potential exceed historical book equity. Alternative valuation metrics such as the price-to-sales ratio of 3.28 and an EV/EBITDA of 14.10 provide context by showing the company commands a high multiple relative to its sales and enterprise earnings, suggesting investors are willing to pay a premium for its revenue base. Price momentum is contextualized by the 52-week high of $118.30 and the 52-week low of $81.36, establishing the range within which the security has traded over the past year. The beta value of 1.11 indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to move with greater amplitude than the overall market index during periods of price fluctuation.

Growth & Income

Growth dynamics are evidenced by a revenue growth rate of 5.9% and an earnings growth rate of 12.5% year-over-year, demonstrating that earnings are expanding at a pace significantly faster than revenue, which often signals improving operational leverage or margin expansion. Regarding income distribution, the company offers a dividend yield of 0.3% with a payout ratio of 13.6%, indicating a conservative dividend policy where the payout is well-covered by earnings and highly sustainable even if profitability fluctuates. The low payout ratio suggests that the majority of earnings are retained within the business to fuel reinvestment in new technologies, acquisitions, or expansion of the diagnostics and research portfolio rather than being distributed to shareholders. The overall growth and income profile presents a company with moderate revenue expansion, accelerating earnings growth, and a minimal but stable dividend yield, catering to investors seeking a blend of capital appreciation potential and income preservation.